Compounds

Semaglutide

IUPAC
18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-2-methylpropanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
Formula
C187H291N45O59
MW
4113.641 g/mol
InChIKey
DLSWIYLPEUIQAV-CCUURXOWSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@H](CC6=CN=CN6)N
PubChem CID
56843331

8,537 patents · 1,345 papers · 4,290 patents and 835 papers in the last 3 years.

Top assignees

  1. Sanofi SA (881 patents)
  2. Novo Nordisk AS (448 patents)
  3. Sanofi Aventis Deutschland GmbH (348 patents)

Notable patents

  1. Preparation method of semaglutide (2015)
  2. Solid synthetic method of semaglutide (2014)
  3. High-expression semaglutide precursor recombinant engineering bacterium and construction method thereof (2021)

Notable papers

  1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2016)
  2. Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)
  3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023)

Full landscape: every top assignee, author, patent, paper, and classification.

Unlock with Cypris

Top assignees

AssigneePatents
Sanofi SA881
Novo Nordisk AS448
Sanofi Aventis Deutschland GmbH348
SHL Medical AG279
Sanofi Aventis France269
Pfizer Inc266
Pfizer Corp SRL248
Merck Sharp and Dohme LLC226
Boehringer Ingelheim International GmbH174
Gilead Sciences Inc167

Top authors

AuthorAffiliationPapers
Ildiko LingvayThe University of Texas Southwestern Medical Center34
Melanie J. DaviesUniversity of Leicester18
Andrei‐Mircea CatarigNovo Nordisk (Denmark)17
Søren RasmussenNovo Nordisk (Denmark)15
A. Michael LincoffCleveland Clinic Lerner College of Medicine14
Barry A. BorlaugMayo Clinic12
Subodh VermaSt. Michael's Hospital12
Barnaby HuntFreiwillige Akademische Gesellschaft11
Julio RosenstockDallas Diabetes Research Center11
John B. BuseUniversity of North Carolina at Chapel Hill10

Top patents

TitleYearAssigneeCitations
Preparation method of semaglutide2015HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD.32
Solid synthetic method of semaglutide2014Hybio Pharmaceutical Co., Ltd.23
High-expression semaglutide precursor recombinant engineering bacterium and construction method thereof2021Beijing Huizhiheng Biological Technology Co Ltd18
Semaglutide purifying method2016Hybio Pharmaceutical Co., Ltd.17
Preparation method of semaglutide and intermediate of semaglutide2016Hybio Pharmaceutical Co., Ltd.11

Top papers

TitleYearCitationsTopic
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes20166538Diabetes Treatment and Management
Once-Weekly Semaglutide in Adults with Overweight or Obesity20214396Diabetes Treatment and Management
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes20232539Diabetes Treatment and Management
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis20201864Liver Disease Diagnosis and Treatment
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes20211847Diabetes, Cardiovascular Risks, and Lipoproteins

Patent classifications

CodeAreaPatents
A61KMedicinal preparations5,602
A61PTherapeutic activity (drug indications)5,259
C07KPeptides2,213
A61MDevices for introducing media into the body1,930
C07DHeterocyclic compounds1,889
C12NMicroorganisms, enzymes606
G16HDigital health, healthcare informatics313
C07BGeneral methods of organic chemistry298
C07CAcyclic and carbocyclic compounds293
G01NInvestigating / analysing materials274

Research topics

TopicPapers
Advanced Drug Delivery Systems1
Diabetes Treatment and Management1

Frequently asked questions

What is the molecular composition of Semaglutide?

Semaglutide has the molecular formula C187H291N45O59 with a molecular weight of 4113.641 Da. Its InChI Key is DLSWIYLPEUIQAV-CCUURXOWSA-N.

Which organizations hold the most patents related to Semaglutide?

Sanofi SA leads with 881 patents, followed by Novo Nordisk AS with 448 patents and Sanofi Aventis Deutschland GmbH with 348 patents. Other major patent holders include SHL Medical AG with 279 patents and Sanofi Aventis France with 269 patents.

What is the scale of research activity on Semaglutide?

As of the data collection period, there are 8,537 total patents related to Semaglutide, with 4,290 filed in the last three years. The scientific literature includes 1,345 papers with 835 published in the last three years.

What are the primary clinical research areas for Semaglutide?

The most cited research focuses on diabetes treatment and management, including studies on cardiovascular outcomes in patients with type 2 diabetes and weight management in adults with overweight or obesity. Additional research addresses applications in liver disease, specifically nonalcoholic steatohepatitis.

What intellectual property classifications are most common for Semaglutide patents?

Patents on Semaglutide are predominantly classified under A61K (pharmaceutical preparations; 5,602 patents) and A61P (specific therapeutic activity of chemical compounds or preparations; 5,259 patents). Peptide and protein chemistry (C07K) accounts for 2,213 patents, and drug delivery methods (A61M) account for 1,930 patents.